{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:13:30Z","timestamp":1762866810211,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.eimce.2021.05.020","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T12:44:20Z","timestamp":1673009060000},"page":"18-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A survey to describe common practices on antifungal monitoring among Spanish clinicians"],"prefix":"10.1016","volume":"41","author":[{"given":"Alicia","family":"G\u00f3mez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Mart\u00edn-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Salavert Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2021.05.020_bib0150","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eimce.2021.05.020_bib0155","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0160","first-page":"1","article-title":"Clinical indications for therapeutic drug monitoring of antifungal agents. In the way for optimizing the treatment of fungal infection","volume":"27","author":"Cendejas-Bueno","year":"2014","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.eimce.2021.05.020_bib0165","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.eimce.2021.05.020_bib0170","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"Gomez-Lopez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2021.05.020_bib0175","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.sjbs.2020.11.002","article-title":"A survey of therapeutic drug monitoring in a teaching hospital","volume":"28","author":"Almohammde","year":"2021","journal-title":"Saudi J Biol Sci"},{"key":"10.1016\/j.eimce.2021.05.020_bib0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jcrc.2020.08.027","article-title":"The ONTAI study \u2013 a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units","volume":"60","author":"Liebchen","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.eimce.2021.05.020_bib0185","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2020.020706","article-title":"Survey on request form content and result reporting in therapeutic drug monitoring service among laboratories in Czechia and Slovakia","volume":"30","author":"Salek","year":"2020","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.eimce.2021.05.020_bib0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.plabm.2017.05.002","article-title":"Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers","volume":"8","author":"Jeon","year":"2017","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.eimce.2021.05.020_bib0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","article-title":"Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eimce.2021.05.020_bib0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.eimce.2021.05.020_bib0205","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0210","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02458-20","article-title":"A New Application of Maldi Biotyper for a potential use on therapeutic drug monitoring of voriconazole","author":"Falces-Romero","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0215","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0220","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0225","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.04.003","article-title":"Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC\/PDA: role of azole metabolic rate","volume":"92","author":"Gomez-Lopez","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.eimce.2021.05.020_bib0230","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","article-title":"Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring","volume":"33","author":"Hassan","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.eimce.2021.05.020_bib0235","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2010.119","article-title":"Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data","volume":"88","author":"Templeton","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimce.2021.05.020_bib0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eimce.2021.05.020_bib0245","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0250","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0255","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2021.05.020_bib0260","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00228-016-2089-y","article-title":"Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis","volume":"72","author":"Li","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eimce.2021.05.020_bib0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimce.2021.05.020_bib0270","doi-asserted-by":"crossref","first-page":"e14137","DOI":"10.1097\/MD.0000000000014137","article-title":"Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections","volume":"98","author":"Miao","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eimce.2021.05.020_bib0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimce.2021.05.020_bib0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12281-020-00371-w","article-title":"Applying pharmacogenomics to antifungal selection and dosing: are we there yet?","volume":"14","author":"Miller","year":"2020","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.eimce.2021.05.020_bib0285","first-page":"619","article-title":"CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs","volume":"73","author":"Sienkiewicz-Oleszkiewicz","year":"2018","journal-title":"Pharmazie"},{"key":"10.1016\/j.eimce.2021.05.020_bib0290","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ejhpharm-2017-001467","article-title":"Do we need to adopt antifungal stewardship programmes?","volume":"27","author":"Ioannidis","year":"2020","journal-title":"Eur J Hosp Pharm"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X22002611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X22002611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:00:26Z","timestamp":1762866026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X22002611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2529993X22002611"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2021.05.020","relation":{},"ISSN":["2529-993X"],"issn-type":[{"type":"print","value":"2529-993X"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A survey to describe common practices on antifungal monitoring among Spanish clinicians","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2021.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}